Avid Bioservices Inc (CDMO)

[biopharm]

David Carbone : Peregrine Pharmaceuticals KOL :

..... remember, David Carbone will be IASLC President in 2015 and now we have more ties to Des Carney and Keith Kerr and BMS is sponsoring this event next month re: the future of biomarkers in NSCLC and also remember, David Carbone and his "blood based biomarkers" previous posts. Nice video below re: Keith Kerr

lets go CALICO... you're still my #1 and time is running out : )

--------------------------------------------------

13th Annual BTOG Conference 2015
Wednesday 28th to Friday 30th January 2015

Session 2

Immunotherapy in Thoracic Tumours

Chairs: Christian Ottensmeier
(UK) and David Chao (UK)

13:00 Vaccine therapy in lung cancer: false promise?
Ken O’Byrne (AU)

13:30 Immune checkpoint inhibitors: (ir)rational drug
development?
David Carbone (US)

14:00 New immunotherapy agents in development
James Spicer (UK)

------------------

The treatment of advanced NSCLC: Future perspectives

Satellite symposium sponsored by MSD
Chair: Dean Fennell (UK)

18:00 Introduction and welcome Dean Fennell (UK)
18:05 Latest advances in the treatment
of advanced NSCLC Naiyer Rizvi (US)
18:35 Discussion
18:45 Close

-------------------

The future of biomarkers in NSCLC: The clinician asks the pathologist

Satellite symposium sponsored by Bristol-Myers Squibb

Des Carney (IE) and Keith Kerr (UK)
19:00 Open
19:45 Close

http://www.btog.org/editorimages/BTOG%202015%20Programme%2017.12.14v2.pdf

-------------------------------------------------------------

Des Carney:

Oncologist at the Mater Hospital, Dr Des Carney says each patient is given treatments specifically designed for their condition - which he says is far more successful.

http://www.newstalk.com/Cancer-and-blood-unit-opens-at-Dublins-Mater-Hospital

----------------------

When I was a young doctor tramping around America looking for training jobs in oncology, the name that all prospective American bosses mentioned when they heard I was Irish, was Des's. He was like a national validation for our professional status, a default national character reference for all young Irish doctors. "You're from Ireland? Same place as Des Carney? Have a job."

http://www.independent.ie/opinion/analysis/proper-reform-of-the-healthcare-system-can-be-cowens-legacy-26435489.html

----------------------------------------------
----------------------------------------------

Keith Kerr:

He has been an IASLC member since 1997 and is a member of the IASLC Pathology Panel, is Pathology Chair for the EORTC lung cancer group, on the ETOP Lungscape steering group, the UKLS lung cancer screening project group and is a member of the International Mesothelioma Pathology panel. He is a member of the Pulmonary Pathology Society Council. He is involved in a number of UK, European and North American initiatives looking at the introduction, operation and quality assurance of guidelines for management and molecular pathology testing in lung cancer.

https://www.abbottpolaris.com/academy-overview/members/keith-kerr.html

--------------

Video:
Description: Dr. Kerr discusses the role of pathology in lung cancer treatment.

http://www.oncologytube.com/v/101759/keith-kerr-md-the-role-of-pathology-in-lung-cancer

--------------

Unlocking the potential of Immuno-Oncology
in lung cancer: a multidisciplinary perspective

Sunday 28 September 2014

Keith Kerr:
Biomarkers in NSCLC: unravelling the data

http://www.esmo.org/content/download/46235/850828/file/ESMO-2014-Satellite-Symposia-Invite-Unlocking-the-Potential-of-Immuno-Oncology-in-Lung-Cancer-a-Multidisciplinary-Perspective-BMS-3.pdf